Sheehan syndrome which is also called post-partum pituitary necrosis refers to the necrosis of cells of the anterior pituitary gland following significant post-partum bleeding, hypovolemia, and shock. Advances in obstetrical care in developed countries has reduced the incidence of this condition. However, it is still a significant cause of morbidity and mortality in less developed countries. British pathologist Harold Leeming Sheehan first described this disorder in 1937.
Sheehan syndrome occurs when the anterior pituitary gland is damaged due to significant blood loss. Classically, this happens after delivery in which the mother loses a significant amount of blood. This blood loss results in the pituitary gland not being able to produce hormones. The diagnosis of Sheehan syndrome is not always apparent immediately after childbirth. Occasionally, the signs and symptoms of Sheehan syndrome may not present until months after childbirth or significant trauma. The first and most common symptom of Sheehan syndrome is the absence of lactation, also known as agalactorrhea. Other symptoms are associated with loss of pituitary gland hormone production and may include amenorrhea or oligomenorrhea, hot flashes, and/or decreased sex drive. Symptoms of hypothyroidism such as fatigue, bradycardia, hypotension, weight gain, and constipation may occur months later along with the loss of axillary and pubic hair. Adrenal insufficiency can also occur with symptoms of fatigue and weight loss. Laboratory values that may support secondary adrenal insufficiency due to Sheehan syndrome could include hyponatremia, anemia, and hypoglycemia.
Sheehan syndrome is rare in developed countries because of advanced obstetrical practices and more exposure to experienced medical providers and medical facilities. Unfortunately, it can be a complication of childbirth in developing and low-income countries. Some studies have placed the incidence of Sheehan syndrome as high as five patients out of 100,000 births.
Pituitary volume and cell count occur in pregnant women in the weeks preceding delivery. This increase is caused principally by hyperplasia of prolactin producing cells (lactotrophs) and hyperplasia of other cells in the anterior pituitary gland. This hyperplasia leads to increased nutritional and metabolic demand by the anterior pituitary gland as a whole, but the blood supply that feeds the anterior pituitary does not increase. The blood supply that feeds the anterior pituitary gland is a relatively low-pressure system. It is theorized that this is the mechanism that makes the pituitary cells more susceptible to ischemia. Consequently, the cells of the anterior pituitary are more prone to necrosis in pregnancies complicated by significant postpartum hemorrhage. The posterior pituitary gland has its blood supply which functions under higher pressure than the anterior pituitary, so it is not usually affected by shock or hypovolemia.
Sheehan syndrome is the clinical manifestation of anterior pituitary cell necrosis and may present as pan-hypopituitarism or as selective loss of pituitary function. Pan-hypopituitarism is a result when many cells of the pituitary are affected, as opposed to only a few cells. It is far more common than the selective loss of pituitary function. Prolactin and growth hormone are the most common hormones affected by selective pituitary necrosis and hypofunction. The posterior pituitary function is usually not affected as stated above. However, diabetes insipidus can occur, but it is a rare manifestation of Sheehan syndrome
Patients may present with an acute or chronic presentation of Sheehan syndrome. The chronic condition of Sheehan syndrome is more common than the acute presentation. Confounding the presentation is that Sheehan syndrome may present months to years after the initial event of hypovolemia and shock.
The acute presenting condition of Sheehan syndrome is usually evident when the mother of the newborn had difficulty with breastfeeding or cannot produce milk at all (agalactorrhea). However, many women are asymptomatic for months to years after childbirth. Women may report difficulties with menses after childbirth, and some may never have menses until Sheehan syndrome is diagnosed and treated. The acute form of Sheehan syndrome can be quite dangerous if not recognized and treated quickly after childbirth. The persistent hypotension and tachycardia can mimic hypovolemia and shock, but hyponatremia and persistent hypoglycemia can help to clinch the diagnosis of Sheehan syndrome.
Chronic Sheehan syndrome is diagnosed due to symptoms that occur due to hypopituitarism, and again, can occur months to years after the initial vascular insult to the pituitary gland. Symptoms of hypothyroidism may occur months after childbirth, and the patient may complain of fatigue, asthenia or weakness, hair loss, constipation, weight gain, problems with focusing or with their attention span, and cold intolerance. Physicians may note hypotension and bradycardia during the physical exam. Patients may also exhibit a secondary adrenal insufficiency which could have symptoms of fatigue and weight loss. Lab values may reflect hypoglycemia, hyponatremia and/or anemia.
Evaluation of anterior pituitary function is done by obtaining blood when a high clinical suspicion is evident to diagnose Sheehan syndrome. The hormones that are manufactured in the anterior pituitary gland are the gonadotropins such as follicle stimulating hormone (FSH) and luteinizing hormone (LH), growth hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH), and thyroid stimulating hormone (TSH). They are affected primarily in a certain order when necrosis occurs, GH first, followed by PRL, FSH, LH, ACTH and then TSH last. Laboratory tests to order would include a CBC with diff, basic metabolic profile, thyroid function tests (TSH, FT3, FT4), FSH, LH, prolactin, estrogen, cortisol, and growth hormone. Finding a low basal hormone level along with a history and physical suggestive of Sheehan syndrome would help to make the diagnosis. Other laboratory tests that may occur with Sheehan syndrome include a normocytic/normochromic anemia, thrombocytopenia, and/or pancytopenia. Hyponatremia and hypoglycemia may also be present as well. Other less common laboratory tests in the workup for Sheehan syndrome that may be abnormal include multiple thrombophilic genetic mutations, low PT and aPTT tests, anti-pituitary antibodies, and anti-hypothalamus antibodies. These tests may be considered after the primary tests to confirm the diagnosis. Also, a magnetic resonance imaging (MRI) evaluation of the pituitary can be done to confirm the diagnosis. An empty sella is present in about 70% of patients, and a partially empty sella is present in about 30% of patients on a later MRI. Acute Sheehan syndrome signs on an MRI may demonstrate acute central infarction without hemorrhage in an enlarged pituitary. As the disease progresses, the MRI may show pituitary gland atrophy and eventually a partial or empty sella.
The basis for treatment of Sheehan syndrome is the lifelong replacement of deficient hormones. Hypothyroidism can be treated with levothyroxine or liothyronine replacement. Cortisol deficiency can be treated by replacement with prednisone or hydrocortisone. Gonadotropin deficiency should be treated with estrogen if the uterus has been removed with a combination of estrogen and progesterone if a uterus is present. Obviously, risks versus benefits must be discussed with that patient in regards to thrombophilia, risks of cancer, myocardial infarction, and others. Growth hormone is probably the most common hormone that needs replacing, and dosage must be individualized to the patient's need. For patients who develop diabetes insipidus, DDAVP is the recommended treatment of choice. Referral to an endocrinologist who is familiar with hypopituitarism and the usage of growth hormone is recommended.
Sheehan syndrome is very rare but carries enormous morbidity. Thus, it is best managed by a multidisciplinary team that includes an endocrinologist, obstetrician, internist, primary care provider, nurse practitioner and a radiologist. The treatment is lifelong replacement of the deficient hormones. Thus, the pharmacist and nurse have to educate the patient on compliance or they risk hormonal crises which can be life threatening. These patients need life long follow up and close monitoring of their hormonal levels. (Level V)
|||Karaca Z,Laway BA,Dokmetas HS,Atmaca H,Kelestimur F, Sheehan syndrome. Nature reviews. Disease primers. 2016 Dec 22 [PubMed PMID: 28004764]|
|||Karaca Z,Hacioglu A,Kelestimur F, Neuroendocrine changes after aneurysmal subarachnoid haemorrhage. Pituitary. 2019 Jan 14; [PubMed PMID: 30637621]|
|||Thompson CJ,Costello RW,Crowley RK, Management of hypothalamic disease in patients with craniopharyngioma. Clinical endocrinology. 2019 Jan 4 [PubMed PMID: 30614015]|
|||Woodmansee WW, Pituitary Disorders in Pregnancy. Neurologic clinics. 2019 Feb; [PubMed PMID: 30470276]|
|||Wang CZ,Guo LL,Han BY,Su X,Guo QH,Mu YM, Pituitary Stalk Interruption Syndrome: From Clinical Findings to Pathogenesis. Journal of neuroendocrinology. 2017 Jan [PubMed PMID: 27917547]|
|||Tıkır B,Göka E,Aydemir MÇ,Gürkan Ş, [Psychotic Disorder and Sheehan's Syndrome: Etiology or Comorbidity?: A Case Report]. Turk psikiyatri dergisi = Turkish journal of psychiatry. 2015 Summer [PubMed PMID: 26111291]|
|||Campos Munoz A,Gupta M, Orthostasis . 2019 Jan [PubMed PMID: 30422533]|
|||Drummond JB,Ribeiro-Oliveira A Jr,Soares BS, Non-Functioning Pituitary Adenomas . 2000 [PubMed PMID: 30521182]|
|||Chiloiro S,Tartaglione T,Angelini F,Bianchi A,Arena V,Giampietro A,Mormando M,Sciandra M,Laino ME,De Marinis L, An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Prospective Single-Center Experience. Neuroendocrinology. 2017 [PubMed PMID: 27165294]|
|||Kanekar S,Bennett S, Imaging of Neurologic Conditions in Pregnant Patients. Radiographics : a review publication of the Radiological Society of North America, Inc. 2016 Nov-Dec [PubMed PMID: 27831835]|
|||Miljic D,Pekic S,Popovic V, Empty Sella . 2000 [PubMed PMID: 30321014]|
|||Matsuzaki S,Endo M,Ueda Y,Mimura K,Kakigano A,Egawa-Takata T,Kumasawa K,Yoshino K,Kimura T, A case of acute Sheehan's syndrome and literature review: a rare but life-threatening complication of postpartum hemorrhage. BMC pregnancy and childbirth. 2017 Jun 14 [PubMed PMID: 28615049]|
|||Zhibin Z,Peng W,Shiyu F,Xinguang Y, Endocrinological outcomes of intraoperative MRI-guided endoscopic transsphenoidal surgery for non-functioning pituitary adenoma. Turkish neurosurgery. 2018 Jun 27; [PubMed PMID: 30649793]|
|||Pfäffle R,Land C,Schönau E,Holterhus PM,Ross JL,Piras de Oliveira C,Child CJ,Benabbad I,Jia N,Jung H,Blum WF, Growth Hormone Treatment for Short Stature in the USA, Germany and France: 15 Years of Surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS). Hormone research in paediatrics. 2018; [PubMed PMID: 30199857]|